West Pharmaceutical Services (NYSE:WST) posted its earnings results on Thursday. The medical instruments supplier reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $0.91 by $0.34, MarketWatch Earnings reports. West Pharmaceutical Services had a net margin of 13.80% and a return on equity of 17.69%. The business had revenue of $527.20 million during the quarter, compared to the consensus estimate of $496.09 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The firm's revenue was up 12.2% on a year-over-year basis. West Pharmaceutical Services updated its FY 2020
Pre-Market guidance to 4.15-4.25 EPS.
The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.11 and a current ratio of 2.84. West Pharmaceutical Services has a one year low of $120.12 and a one year high of $257.92. The company's fifty day moving average price is $222.90 and its two-hundred day moving average price is $182.27. The stock has a market cap of $18.80 billion, a PE ratio of 72.75, a price-to-earnings-growth ratio of 4.67 and a beta of 1.13.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of ∞. The ex-dividend date is Tuesday, July 28th. West Pharmaceutical Services's dividend payout ratio (DPR) is 19.75%.
WST has been the topic of several analyst reports. Bank of America upgraded shares of West Pharmaceutical Services from a "neutral" rating to a "buy" rating and set a $280.00 price target on the stock in a research note on Tuesday. Zacks Investment Research reiterated a "buy" rating and set a $219.00 price target on shares of West Pharmaceutical Services in a research note on Sunday, May 3rd. Finally, BofA Securities upgraded shares of West Pharmaceutical Services from a "neutral" rating to a "buy" rating and set a $280.00 price target on the stock in a research note on Tuesday.
In other West Pharmaceutical Services news, insider Silji Abraham sold 500 shares of the business's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $200.66, for a total value of $100,330.00. Following the sale, the insider now owns 5,041 shares in the company, valued at approximately $1,011,527.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 14,192 shares of the business's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $196.90, for a total transaction of $2,794,404.80. Following the completion of the sale, the vice president now owns 12,937 shares in the company, valued at approximately $2,547,295.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,497 shares of company stock worth $3,236,566. 1.60% of the stock is owned by corporate insiders.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
See Also: What are the benefits of investing in REITs?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
6 Stocks That May Not Survive the Coronavirus
Companies that are in a shaky financial position may sometimes attract investors in a bull market. Traders seeking a short-term profit can often use an oversold condition to capture a quick gain. But in a bear market, these companies frequently are left on the sidelines.
But a declining stock price by itself should not be enough to scare investors off. What investors really need to pay attention to is the company’s ability to finance existing debt or take on additional debt. Companies with low credit ratings face the problem of having too much debt on their books and an inability to finance it at more favorable rates.
That’s one reason we’ve put together this presentation that highlights 6 companies that may not survive the coronavirus. These companies have low stock prices. In fact, many of them are, or will be, in danger of being delisted if they cannot bring their stock above the $1 threshold. And on top of that, these companies each carry credit ratings of CCC+ or lower and are at risk of seeing those ratings even go lower.
Each of the companies presented here are considered to be among the weakest, if not the weakest, in their sector. If you have any of these falling knives in your portfolio now is the time to cut your losses and walk away.
View the "6 Stocks That May Not Survive the Coronavirus".